RESUMEN
The development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A is a serious complication leading to poorly controlled bleeding and increased morbidity. No treatment has been proven to reduce high titre antibodies in patients who fail immune tolerance induction or are not candidates for it. The Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (RICH) study was a phase II trial to assess whether rituximab can reduce anamnestic FVIII antibody (inhibitor) titres. Male subjects with severe congenital haemophilia A and an inhibitor titre ≥5 Bethesda Units/ml (BU) following a FVIII challenge infusion received rituximab 375 mg/m² weekly for weeks 1 through 4. Post-rituximab inhibitor titres were measured monthly from week 6 through week 22 to assess treatment response. Of 16 subjects who received at least one dose of rituximab, three (18.8%) met the criteria for a major response, defined as a fall in inhibitor titre to <5 BU, persisting after FVIII re-challenge. One subject had a minor response, defined as a fall in inhibitor titre to <5 BU, increasing to 5-10 BU after FVIII re-challenge, but <50% of the original peak inhibitor titre. Rituximab is useful in lowering inhibitor levels in patients, but its effect as a solo treatment strategy is modest. Future studies are indicated to determine the role of rituximab as an adjunctive therapy in immune tolerisation strategies.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Hemofilia A/tratamiento farmacológico , Inmunosupresores/administración & dosificación , Adolescente , Adulto , Anticuerpos Bloqueadores/metabolismo , Anticuerpos Monoclonales de Origen Murino/efectos adversos , Formación de Anticuerpos/efectos de los fármacos , Antígenos CD20/inmunología , Coagulación Sanguínea/efectos de los fármacos , Coagulación Sanguínea/genética , Niño , Preescolar , Factor VIII/administración & dosificación , Factor VIII/inmunología , Estudios de Seguimiento , Hemofilia A/genética , Humanos , Inmunosupresores/efectos adversos , Masculino , Rituximab , Resultado del Tratamiento , Estados Unidos , Adulto JovenRESUMEN
AIM: A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation. METHODS: Data were extracted of the RE-LY study of dabigatran 110 mg bid and dabigatran 150 mg bid, the ROCKET AF trial of rivaroxaban and the ARISTOTLE trial of apixaban for the composite outcome of ischemic stroke and systemic embolism, for major bleeding, intracerebral bleeding, mortality and myocardial infarction. RESULTS: Dabigatran (150 mg bid) showed superior efficacy in preventing ischemic stroke plus systemic embolism to dabigatran (110 mg bid, P=0.0364) and rivaroxaban (P=0.0388). Apixaban had equivalent efficacy with rivaroxaban and dabigatran (either dose). Apixaban was safer (less major bleeding) than dabigatran (150 mg bid, P=0.036) or rivaroxaban (P=0.0002). Intracerebral hemorrhage occurred with equal frequency for all agents except for rivaroxaban (higher risk than dabigatran 110 mg bid, P=0.0070). Myocardial infarction occurred less frequently with rivaroxaban and apixaban compared to either dose of dabigatran (all P<0.05). CONCLUSION: All-cause mortality was not different for any agent or regimen. In the absence of head-to-head comparisons, this network meta-analysis suggests that apixaban and dabigatran 110 mg bid may offer the best benefit-risk balance for stroke prevention in non-valvular atrial fibrillation. Dabigatran 150 mg bid may be preferred for patients with a high risk for embolism.
Asunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Bencimidazoles/uso terapéutico , Embolia/prevención & control , Morfolinas/uso terapéutico , Pirazoles/uso terapéutico , Piridonas/uso terapéutico , Accidente Cerebrovascular/tratamiento farmacológico , Tiofenos/uso terapéutico , beta-Alanina/análogos & derivados , Administración Oral , Anciano , Anticoagulantes/administración & dosificación , Anticoagulantes/efectos adversos , Fibrilación Atrial/complicaciones , Fibrilación Atrial/mortalidad , Bencimidazoles/administración & dosificación , Bencimidazoles/efectos adversos , Hemorragia Cerebral/inducido químicamente , Distribución de Chi-Cuadrado , Dabigatrán , Embolia/etiología , Embolia/mortalidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Morfolinas/administración & dosificación , Morfolinas/efectos adversos , Infarto del Miocardio/etiología , Oportunidad Relativa , Pirazoles/administración & dosificación , Pirazoles/efectos adversos , Piridonas/administración & dosificación , Piridonas/efectos adversos , Medición de Riesgo , Factores de Riesgo , Rivaroxabán , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/mortalidad , Tiofenos/administración & dosificación , Tiofenos/efectos adversos , Resultado del Tratamiento , beta-Alanina/administración & dosificación , beta-Alanina/efectos adversos , beta-Alanina/uso terapéuticoRESUMEN
BACKGROUND: Current treatment of acute peripheral artery or bypass graft occlusion utilizes catheter-directed thrombolysis of a plasminogen activator (PA). Plasmin is a direct-acting thrombolytic with a striking safety advantage over PA in preclinical models. OBJECTIVES: To report the first use of purified plasmin for acute lower extremity arterial or bypass graft thrombosis in a phase I dose-escalation study of a catheter-delivered agent. METHODS: Eighty-three patients with non-embolic occlusion of infrainguinal native arteries or bypass grafts were enrolled (safety population) into seven sequential dose cohorts to receive 25-175 mg of plasmin by intrathrombus infusion over 5 h. Arteriograms were performed at baseline, 2 h, and 5 h, and subjects were monitored for 30 days for clinical outcomes and laboratory parameters of systemic fibrinolysis. RESULTS: Major bleeding occurred in four patients (4.8%), and minor bleeding alone in 13 (15.7%), with no trend towards more bleeding at higher dosages of plasmin. There was a trend towards lower plasma concentrations of fibrinogen, α(2) -antiplasmin and α(2) -macroglobulin with increasing doses of plasmin, but the nadir fibrinogen concentration was > 350 mg dL(-1) at the highest plasmin dose. Individual nadir values were above 200 mg dL(-1) in 82 of 83 subjects, and were not different in patients with or without bleeding. Thrombolysis (≥ 50%) occurred in 79% of subjects receiving 125-175 mg of plasmin, as compared with 50% who received 25-100 mg. CONCLUSIONS: Catheter-delivered plasmin can be safely administered to patients with acute lower extremity arterial occlusion at dosages of 25-175 mg.
Asunto(s)
Arteriopatías Oclusivas/tratamiento farmacológico , Cateterismo Periférico , Fibrinolisina/administración & dosificación , Fibrinolíticos/administración & dosificación , Oclusión de Injerto Vascular/tratamiento farmacológico , Extremidad Inferior/irrigación sanguínea , Terapia Trombolítica/métodos , Enfermedad Aguda , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Arteriopatías Oclusivas/sangre , Arteriopatías Oclusivas/diagnóstico por imagen , Biomarcadores/sangre , Brasil , Cateterismo Periférico/efectos adversos , Relación Dosis-Respuesta a Droga , Europa (Continente) , Femenino , Fibrinógeno/metabolismo , Fibrinolisina/efectos adversos , Fibrinolíticos/efectos adversos , Oclusión de Injerto Vascular/sangre , Oclusión de Injerto Vascular/diagnóstico por imagen , Hemorragia/inducido químicamente , Humanos , Infusiones Intraarteriales , Masculino , Persona de Mediana Edad , Radiografía , Sudáfrica , Terapia Trombolítica/efectos adversos , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos , Adulto Joven , alfa 2-Antiplasmina/metabolismo , alfa-Macroglobulinas/metabolismoRESUMEN
Two issues have held the focus of thrombolysis research for over 50 years, namely, choosing between a plasminogen activator (PA) or plasmin as the best therapeutic agent and choosing between systemic or local administration. The original plasmin product of the 1950s was both ineffective and contaminated with PA, and catheter technology was not yet developed for routine clinical use. For decades, clinical practice has focused on PA and systemic administration, but today, PAs are often administered by catheter into thrombosed vessels, notably for peripheral arterial and graft occlusion and deep vein thrombosis, and increasingly for acute ischaemic stroke. Despite using catheter-delivered therapy, bleeding complications still occur, most severely expressed as symptomatic intracranial haemorrhage. New experimental data indicate that we should now reconsider plasmin as a viable, even preferable, thrombolytic agent. Plasmin requires catheter delivery to achieve thrombolysis, but this technical issue has been solved with modern technology and widespread presence of interventional suites. After local administration, plasmin will lyse thrombi; thereafter, any plasmin in the circulation will be rapidly neutralised. Pre-clinical studies confirm that plasmin has marked haemostatic safety advantage over t-PA. After more than 50 years, the field has come full circle, and plasmin as the thrombolytic agent and catheter use for local delivery of agent may represent a step forward in thrombolytic therapy.
Asunto(s)
Investigación Biomédica/historia , Fibrinolisina/uso terapéutico , Fibrinólisis , Trombosis/tratamiento farmacológico , Investigación Biomédica/tendencias , Ensayos Clínicos como Asunto , Fibrinolisina/efectos adversos , Historia del Siglo XX , Historia del Siglo XXIRESUMEN
BACKGROUND: Heparin-induced thrombocytopenia is an antibody-mediated disorder exhibiting variable frequency in different clinical settings. Antibodies recognize PF4/heparin complexes formed at optimal stoichiometric molar ratios. OBJECTIVE: To identify clinical factors influencing risk of anti-PF4/heparin immunization. PATIENTS/METHODS: We performed observational studies and exploratory analyses of the frequency of anti-PF4/heparin antibody formation in 6324 patients who received enoxaparin or fondaparinux in four randomized controlled trials of postorthopedic surgery thromboprophylaxis. Variables included surgery type (knee vs. hip), timing of first anticoagulant dose (pre- vs. postsurgery), circumstances of surgery (elective vs. hip fracture), anticoagulant (enoxaparin vs. fondaparinux) and body-mass index (BMI). We applied a stoichiometry-based model that predicts immunization risk based on expected differences in PF4/anticoagulant ratios in different settings, and specifically used this model to predict the effect of increasing BMI quartiles upon relative risk (RR) of immunization for fondaparinux vs. enoxaparin. RESULTS: Anti-PF4/heparin immunization was more frequent after knee vs. hip surgery (particularly for enoxaparin), and when enoxaparin was given post- rather than pre-elective surgery; however, the opposite occurred with hip fracture surgery, that is, antibody formation was more frequent when enoxaparin or fondaparinux was given presurgery. The RR of immunization for fondaparinux vs. enoxaparin decreased significantly for increasing BMI quartiles, an effect predominantly because of increasing immunization with enoxaparin at increasing BMI quartiles. CONCLUSIONS: Several non-drug factors--including type and circumstances of surgery, timing of first anticoagulant dose and BMI--influence risk of anti-PF4/heparin antibody formation, consistent with a stoichiometry-based immunization model of PF4 and anticoagulant ratios occurring during the early peri-operative period.
Asunto(s)
Anticuerpos/sangre , Anticoagulantes/efectos adversos , Enoxaparina/efectos adversos , Procedimientos Ortopédicos/efectos adversos , Factor Plaquetario 4/inmunología , Polisacáridos/efectos adversos , Trombocitopenia/inducido químicamente , Trombosis/prevención & control , Anticoagulantes/administración & dosificación , Anticoagulantes/inmunología , Índice de Masa Corporal , Esquema de Medicación , Enoxaparina/administración & dosificación , Enoxaparina/inmunología , Medicina Basada en la Evidencia , Fondaparinux , Humanos , Modelos Estadísticos , Polisacáridos/administración & dosificación , Polisacáridos/inmunología , Ensayos Clínicos Controlados Aleatorios como Asunto , Medición de Riesgo , Factores de Riesgo , Trombocitopenia/inmunología , Trombosis/etiología , Trombosis/inmunologíaRESUMEN
Direct fibrinolytics are proteolytic enzymes that degrade fibrin without requiring an intermediate step of plasminogen activation. This review summarizes the current information available for five such agents, namely, plasmin (the prototypical form), three derivatives of plasmin (mini-plasmin, micro-plasmin, and delta-plasmin), and alfimeprase, a recombinant variant of a snake venom alpha-fibrinogenase, fibrolase. Biochemical attributes of molecular size, fibrin binding and inhibitor neutralization are compared. Preclinical investigations that assess the potential for thrombolytic efficacy in vitro and in animal models of vascular occlusion and for hemostatic safety in animal models of bleeding are detailed. Clinical potential has been assessed in patients with peripheral arterial and graft occlusion, acute ischemic stroke, and access catheter and hemodialysis shunt occlusions. The direct fibrinolytic agents have impressive biochemical and preclinical foundations for ultimate clinical application. However, clinical trial results for micro-plasmin and alfimeprase have not measured up to their anticipated benefit. Plasmin has thus far shown encouraging hemostatic safety, but efficacy data await completion of clinical trials. Whether direct fibrinolytics will provide clinical superiority in major thrombotic disorders over currently utilized indirect fibrinolytics such as tissue plasminogen activator remains to be determined.
Asunto(s)
Enfermedades Cardiovasculares/tratamiento farmacológico , Fibrina/metabolismo , Fibrinólisis/efectos de los fármacos , Fibrinolíticos/uso terapéutico , Terapia Trombolítica , Animales , Enfermedades Cardiovasculares/sangre , Modelos Animales de Enfermedad , Fibrinolisina/uso terapéutico , Fibrinolíticos/efectos adversos , Fibrinolíticos/farmacología , Hemorragia/inducido químicamente , Humanos , Metaloendopeptidasas/uso terapéutico , Fragmentos de Péptidos/uso terapéutico , Terapia Trombolítica/efectos adversosRESUMEN
BACKGROUND: Hemodialysis (HD) grafts often fail because of stenosis at the venous anastomosis and thrombotic occlusion. Percutaneous management relies on thrombolysis with plasminogen activators, mechanical removal of thrombus, and angioplasty of the stenotic lesion. OBJECTIVES: This report describes a phase I trial using Plasmin (Human) TAL 05-00018, a direct-acting fibrinolytic agent, to evaluate safety and, secondarily, to establish effective thrombolytic dosing. PATIENTS/METHODS: Six cohorts of five patients with acute HD graft occlusion documented by angiography were treated with escalating dosages of plasmin (1, 2, 4, 8, 12, and 24 mg) infused over 30 min via criss-crossed pulse-spray catheters within the graft. The primary efficacy endpoint was > or =50% thrombolysis, as determined by comparison of pre-plasmin and 30-min post-plasmin fistulograms. RESULTS: Of 31 subjects who received study drug (safety population), one withdrew and 30 completed the trial (evaluable for efficacy). There was no significant change in plasma alpha-2 antiplasmin or fibrinogen concentration, major bleeding did not occur, and there were no deaths. Serious adverse events in four patients were not related to the study drug. There was a dose-response relationship for the primary efficacy endpoint, all five subjects receiving 24 mg achieving >75% lysis. CONCLUSIONS: This first phase I study of Plasmin (Human) TAL 05-00018, infused into thrombosed HD grafts, documents safety at dosages of 1-24 mg and an effective thrombolytic dosage of 24 mg. The results establish a foundation for further clinical study of catheter-based plasmin administration in thrombotic disorders.
Asunto(s)
Fibrinolisina/administración & dosificación , Fibrinolisina/farmacología , Diálisis Renal/métodos , Terapia Trombolítica/instrumentación , Adulto , Anciano , Anciano de 80 o más Años , Coagulación Sanguínea , Estudios de Cohortes , Relación Dosis-Respuesta a Droga , Femenino , Fibrinolisina/química , Fibrinolisina/metabolismo , Fibrinolíticos/farmacología , Humanos , Isquemia/patología , Masculino , Persona de Mediana Edad , Terapia Trombolítica/métodos , Trombosis/patologíaRESUMEN
BACKGROUND: Bleeding symptoms are so commonly reported that it is not known whether they associate causally or coincidentally with mild but measurable primary hemostatic defects. OBJECTIVES/PATIENTS/METHODS: In order to evaluate if the mild primary hemostatic defects are truly causative of increased bleeding symptoms, we surveyed a population of healthy teenagers for bleeding symptoms. Using a case-control approach, we then estimated the risk of excessive bleeding associated with low von Willebrand factor (defined as VWF below the 5th percentile of a normal reference population), and with mild platelet dysfunction [PD, defined as concurrent reduced platelet aggregation responses to two agonists (adenosine diphosphate and epinephrine)]. RESULTS: Excessive bleeding was present in 63 out of 809 teenagers (7.8%). Among the 49 cases who were tested for VWF, low values by three measures were more commonly present than in 166 controls, specifically, ristocetin cofactor (RCo) activity [20.4% vs. 5.4%, odds ratio (OR) 4.5], collagen binding (14.3% vs. 4.2%, OR 3.8), and antigen level (20.4% vs. 6.0%, OR 4.0). The low RCo values ranged from 35 to 45 U dL(-1) except for a single case with 26 U dL(-1). Of the 47 teenagers with excessive bleeding who underwent platelet aggregation studies, reduced responses were more common than in controls (12.8% vs. 4.4%, OR 3.2). Twenty-nine per cent of cases with excessive bleeding had either low RCo or PD. CONCLUSION: Almost one in three teenagers who report excessive bleeding is likely to have a measurable hemostatic disturbance manifested either by marginally low VWF (by three measures) or by mild PD.
Asunto(s)
Trastornos de las Plaquetas Sanguíneas/complicaciones , Hemorragia/etiología , Factor de von Willebrand/análisis , Adolescente , Estudios de Casos y Controles , Femenino , Hemorragia/epidemiología , Humanos , Masculino , Agregación Plaquetaria , Pruebas de Función Plaquetaria , Riesgo , Encuestas y CuestionariosRESUMEN
BACKGROUND: Increasing circulating magnesium concentrations to 2-fold over normal baseline may afford a neuroprotective effect in patients with acute cerebral ischemia. OBJECTIVES: As patients receiving magnesium sulfate (MgSO(4)) in human clinical trials may also be candidates for subsequent thrombolytic therapy with tissue plasminogen activator (t-PA), preclinical assessment of possible inhibition or potentiation of fibrinolytic activity by MgSO(4) has important clinical relevance. METHODS: We utilized an in vitro system, in which D-dimer release served as a reflection of t-PA-induced clot lysis, to measure the effect of magnesium at the target concentration being tested in human stroke clinical trials, and at 2- and 3-fold higher levels. Clots from normal volunteers were exposed to t-PA at concentrations that correspond to therapeutic or endogenous plasma t-PA levels. RESULTS: MgSO(4) had no effect on t-PA-induced clot lysis at up to 3-fold target magnesium concentration (6x normal serum concentration). CONCLUSIONS: MgSO(4) concentrations well above the targeted level in therapeutic stroke trials does not affect t-PA-induced fibrinolytic activity, and therefore is a suitable agent for trials of combined neuroprotective and thrombolytic therapy in patients with acute ischemic stroke.
Asunto(s)
Fibrinólisis/efectos de los fármacos , Sulfato de Magnesio/farmacología , Terapia Trombolítica/métodos , Activador de Tejido Plasminógeno/farmacología , Relación Dosis-Respuesta a Droga , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Humanos , Técnicas In Vitro , Sulfato de Magnesio/administración & dosificación , Sulfato de Magnesio/sangre , Masculino , Fármacos Neuroprotectores/farmacología , Accidente Cerebrovascular/tratamiento farmacológico , Activador de Tejido Plasminógeno/uso terapéuticoRESUMEN
The present study was conducted in order to determine the prevalence of vaginal colonization by Candida spp in elderly residents of a long-term-care hospital and to examine the determinants of vaginal candidiasis. Vaginal swabs for Gram stain and culture were obtained from 106 bedridden residents of a long-term-care hospital (study group; mean age, 83+/-7 years) and a control group of 50 similarly aged women admitted to an acute-care hospital for non-genital problems (mean age, 81+/-8 years). The characteristics of patients who tested positive for Candida spp were compared with those who tested negative. Candida spp were isolated from 34 (32%) patients in the study group and from four (8%) control patients (p=0.001). In the study group, Candida glabrata was by far the most common species isolated (51.2%). The warm and moist environment in the perineal area created by diaper use in incontinent individuals, together with decubitus ulcers and immobilization, which are common in elderly patients receiving long-term care, might be responsible for the high occurrence of vaginal colonization with Candida in these women.
Asunto(s)
Candidiasis Vulvovaginal/microbiología , Candidiasis/microbiología , Vagina/microbiología , Anciano , Anciano de 80 o más Años , Candida/aislamiento & purificación , Candidiasis/epidemiología , Candidiasis Vulvovaginal/epidemiología , Femenino , Humanos , Cuidados a Largo Plazo , PrevalenciaAsunto(s)
Anticoagulantes/uso terapéutico , Síndrome Antifosfolípido/tratamiento farmacológico , Administración Oral , Anticoagulantes/administración & dosificación , Hemorragia , Humanos , Relación Normalizada Internacional , Proyectos de Investigación , Estudios Retrospectivos , Warfarina/administración & dosificación , Warfarina/uso terapéuticoRESUMEN
Patients with haemophilia are at increased risk of hepatitis C infection because of prior transfusion of blood products. Virtually all haemophiliacs who received pooled blood products before the mid-1980s have been infected with hepatitis C. A liver biopsy is important to identify the extent of liver disease, and to help determine the necessity of interferon therapy. With factor replacement, in-hospital liver biopsy is safe. Thirty patients with haemophilia were evaluated for chronic hepatitis C infection. Eleven patients subsequently underwent successful transjugular liver biopsy in the outpatient setting after appropriate factor replacement. Mean +/- SD pre- and posthaemoglobin values were 15.8 +/- 0.79 and 14.4 +/- 0.71 g dL(-1) (P = ns). There was no significant change in heart rate, systolic or diastolic blood pressure during the monitoring period (P = ns) and no major complication was noted in perioperative follow-up. The mean length of the liver biopsy specimens was 1.7 +/- 0.3 cm, mean grade was 2 +/- 0.6 and mean stage was 2.3 +/- 1.2. Our experience demonstrates that outpatient transjugular liver biopsy can be safely performed in patients with haemophilia in the outpatient setting, avoiding the cost and need for hospital admission.
Asunto(s)
Hemofilia A , Hepatitis C Crónica/diagnóstico , Hígado/patología , Adulto , Procedimientos Quirúrgicos Ambulatorios , Biopsia/métodos , Factor IX/análisis , Factor VIII/análisis , Factor VIII/uso terapéutico , Humanos , Masculino , Complicaciones Posoperatorias/prevención & controlRESUMEN
Plasmin is a direct thrombolytic which has been shown to have a strikingly favorable benefit to risk profile in comparison with plasminogen activators, notably tissue plasminogen activator (t-PA). As heparin is known to increase the risk of hemorrhage when co-administered with a plasminogen activator, we asked whether adjunct antithrombotic agents such as aspirin and heparin would affect the safety of plasmin. Three groups of rabbits were administered plasmin at a dose (4 mg kg-1) designed to induce significant decreases in antiplasmin, fibrinogen and factor (F)VIII, to about 25, 40 and 40%, respectively, of baseline values, but not cause prolongation of the ear puncture bleeding time. In a blinded and randomized trial, the results show that an intravenous aspirin bolus plus heparin administered as a bolus followed by a maintenance continuous infusion did not significantly prolong the bleeding time during plasmin infusion. These data indicate that in the rabbit, concomitant use of aspirin plus heparin does not affect the safety of a therapeutic dose of plasmin.
Asunto(s)
Fibrinolíticos/administración & dosificación , Fibrinolíticos/efectos adversos , Hemorragia/inducido químicamente , Animales , Aspirina/administración & dosificación , Aspirina/efectos adversos , Tiempo de Sangría , Interacciones Farmacológicas , Quimioterapia Combinada , Fibrinolisina/administración & dosificación , Fibrinolisina/efectos adversos , Heparina/administración & dosificación , Heparina/efectos adversos , Modelos Animales , Conejos , Terapia Trombolítica/efectos adversosRESUMEN
We report a patient with hemoglobin sickle cell-hemoglobin C disease who developed the clinical syndrome of thrombotic thrombocytopenic purpura (TTP) during admission for typical acute pain crisis. The potential for multiorgan involvement secondary to vaso-occlusive crisis complicated the diagnosis and overlapped with the patient's clinical presentation of chronic bone pain and hemolytic anemia. Clinical improvement and normalization of laboratory parameters followed rapidly in response to plasma exchange therapy.
Asunto(s)
Enfermedad de la Hemoglobina SC/complicaciones , Púrpura Trombocitopénica Trombótica/complicaciones , Adulto , Humanos , Masculino , Dolor/etiología , Manejo del Dolor , Intercambio Plasmático , Púrpura Trombocitopénica Trombótica/sangre , Púrpura Trombocitopénica Trombótica/terapiaRESUMEN
BACKGROUND: Unfractionated heparin (UFH) is safe and effective for thromboprophylaxis, but its use is limited to parenteral administration. A novel drug delivery agent (SNAC) has been developed to accomplish the oral delivery of heparin. OBJECTIVE: This report describes the foundation for dose selection and use of oral heparin/SNAC in patients undergoing elective total hip arthroplasty (THA). PATIENTS AND METHODS: To develop a treatment regimen for clinical study, a multiple dose Phase I pharmacokinetic (PK) study in healthy volunteers compared oral heparin/SNAC (90 000 U heparin) with subcutaneous UFH (5000 U). On this basis, we carried out a double-blind, randomized, multicenter study comparing subcutaneous UFH (5000 U) with oral heparin/SNAC at either 60 000 or 90 000 U heparin in 123 patients undergoing elective THA. Patients received, postoperatively, one of the three treatments every 8 h for a total of 12 doses and were followed for 35 days post surgery. RESULTS: In the Phase I study, anti-factor Xa activity peaked at 45-60 min following oral heparin/SNAC, returning to baseline at 4 h. RESULTS of the randomized trial in THA patients showed that venous thromboembolic events (n = 6), major bleeding events (n = 5) and need for transfusion (n = 23) were distributed evenly among the three treatment groups, UFH and both doses of oral heparin/SNAC. CONCLUSION: This is the first demonstration that oral heparin/SNAC can be safely delivered to the postoperative THA patient, and provides the basis for a larger clinical trial to assess the prophylactic efficacy of heparin/SNAC.
Asunto(s)
Artroplastia de Reemplazo de Cadera/efectos adversos , Portadores de Fármacos , Heparina/administración & dosificación , Trombosis/prevención & control , Adolescente , Adulto , Anciano , Transfusión Sanguínea , Caprilatos , Inhibidores del Factor Xa , Femenino , Hemorragia/inducido químicamente , Heparina/efectos adversos , Heparina/farmacocinética , Humanos , Masculino , Persona de Mediana Edad , Tiempo de Tromboplastina Parcial , Farmacocinética , Cuidados Posoperatorios , Trombosis/tratamiento farmacológicoRESUMEN
While protamine sulfate reverses the anticoagulant effect of standard heparin, there currently is no effective antidote for low molecular weight heparin (LMWH)-induced bleeding. Recently, recombinant activated factor VII (rFVIIa) was approved by the FDA for use in hemophilia patients with factor (F)VIII or FIX inhibitors. However, this new pro-hemostatic agent has potential utility in other clinical scenarios. In this study, we utilized a well-characterized rabbit ear puncture model to test the efficacy of rFVIIa to reverse LMWH-induced prolonged bleeding. Animals were first treated with bolus intravenous LMWH (1800 anti-FXa U kg(-1)) which increased the primary bleeding time approximately fourfold and raised the plasma anti-FXa activity immediately and continuously throughout the 90-min experiment. In a randomized and blinded fashion, animals then received either rFVIIa (400 microg kg(-1)) or placebo by bolus intravenous injection, following which the ear puncture bleeding times were measured, along with blood levels of heparin (anti-FXa activity) and FVII. FVII activity increased 5.3-fold over baseline in treated animals, decreasing by only 24% over the full observation period. The rFVIIa-treated animals showed a slight decrease in bleeding time immediately after injection, but there was no statistically significant difference in bleeding after rFVIIa or placebo administration. In this study using a rabbit ear bleeding model, rFVIIa was not an effective antidote to LMWH-induced bleeding. However, the bolus injection of LMWH produced a very high blood anti-FXa level, which may have precluded rFVIIa effectiveness.
Asunto(s)
Factor VII/uso terapéutico , Hemorragia/tratamiento farmacológico , Heparina de Bajo-Peso-Molecular/efectos adversos , Proteínas Recombinantes/uso terapéutico , Animales , Antídotos , Tiempo de Sangría , Evaluación de Medicamentos , Factor VII/farmacología , Factor VIIa , Hemorragia/inducido químicamente , Hemostasis/efectos de los fármacos , Cinética , Masculino , Conejos , Proteínas Recombinantes/farmacología , TinzaparinaAsunto(s)
Terapia Trombolítica/métodos , Animales , Ensayos Clínicos como Asunto , Contraindicaciones , Fibrinolíticos/efectos adversos , Fibrinolíticos/farmacología , Fibrinolíticos/uso terapéutico , Hemorragia/inducido químicamente , Hemorragia/terapia , Humanos , Terapia Trombolítica/efectos adversos , Enfermedades Vasculares/complicaciones , Enfermedades Vasculares/tratamiento farmacológico , Enfermedades Vasculares/mortalidadRESUMEN
The direct fibrinolytic enzyme, plasmin, was compared with tissue plasminogen activator (TPA) in rabbit models of local thrombolysis and fibrinolytic hemorrhage. Plasmin was produced by solid-phase urokinase activation of plasminogen and purified on benzamidine Sepharose. Applied as an intra-arterial infusion into the thrombosed abdominal aorta under conditions of unimpeded blood flow, plasmin (4 mg/kg) and TPA (2 mg/kg) achieved equivalent clot dissolution and flow restoration. Using the model of restricted blood flow into the thrombosed aorta, which limits local plasminogen supply, plasmin was superior to TPA in clot lysis and vascular reperfusion. Using similar dosages of plasmin (2 or 4 mg/kg) and TPA (1 or 2 mg/kg) in the earpuncture rebleed model. TPA induced rebleeding in a dose-dependent manner from prior puncture sites in 9 of 10 animals, while none of the 10 animals exposed to plasmin rebled from these sites. These results suggest that plasmin is an effective, unique thrombolytic agent, distinguished from the plasminogen activators in current usage by its striking safety profile.
Asunto(s)
Enfermedades de la Aorta/tratamiento farmacológico , Fibrinolisina/uso terapéutico , Fibrinólisis/efectos de los fármacos , Fibrinolíticos/uso terapéutico , Hemorragia/prevención & control , Terapia Trombolítica , Trombosis/tratamiento farmacológico , Activador de Tejido Plasminógeno/uso terapéutico , Animales , Aorta Abdominal , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Oído , Fibrinolisina/farmacología , Fibrinolíticos/farmacología , Hemorragia/inducido químicamente , Infusiones Intraarteriales , Conejos , Recurrencia , Seguridad , Terapia Trombolítica/efectos adversos , Activador de Tejido Plasminógeno/farmacologíaRESUMEN
Diabetes is an established risk factor for reinfarction and cardiac death in postinfarction patients. Since the underlying mechanism of diabetes-related risk is not fully understood we aimed to evaluate the association between lipids, thrombogenic factors and diabetes in postinfarction patients. The study population consisted of 1,045 postinfarction patients (846 non-diabetic, 125 non-insulin- and 74 insulin-requiring diabetics) with the following blood tests performed 2 months after an index myocardial infarction: lipoprotein (a), apolipoprotein-B, apolipoprotein-A, cholesterol, HDL cholesterol, triglycerides, insulin, von Willebrand factor (vWF), fibrinogen, factor VII, D-dimer, and plasminogen activator inhibitor (PAI-1). After adjustment for relevant clinical covariates, non-insulin-requiring diabetes was significantly (p < 0.05) associated with elevated levels of (odd ratios per 1 log unit increase in parenthesis) vWF (1.74) and PAI-1 (1.42) whereas insulin requiring diabetes was associated with even more elevated levels of vWF (4.68), but not with increased levels of PAI-1. No significant differences in lipid levels were observed among three groups. In conclusion, increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients, suggesting that endothelial damage is the primary mechanisms contributing to an increased occurrence of vascular and cardiac events in diabetic postinfarction patients.
Asunto(s)
Diabetes Mellitus/sangre , Infarto del Miocardio/sangre , Factor de von Willebrand/análisis , Adulto , Anciano , Glucemia/análisis , Proteínas Sanguíneas/análisis , Convalecencia , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 2/sangre , Endotelio Vascular/patología , Femenino , Humanos , Insulina/sangre , Lípidos/sangre , Lipoproteínas/sangre , Masculino , Persona de Mediana Edad , Análisis Multivariante , New York/epidemiología , Oportunidad Relativa , Inhibidor 1 de Activador Plasminogénico/análisis , Factores de RiesgoRESUMEN
The heparins, (unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH)) given by subcutaneous or intravenous injection have been used extensively in the prevention and treatment of both venous and arterial thromboembolic disorders. The increasing use of the heparins, LMWHs in particular, in the out of hospital setting has stimulated interest in the development of orally absorbable antithrombotic agents that require little or no monitoring, and this includes the heparins. UFH or LMWH delivered orally has been shown to have an antithrombotic effect in animal thrombosis models although there is little change in plasma coagulation tests. The addition of a simple organic chemical N -(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) to UFH markedly enhances its absorption. A phase II study in patients undergoing total hip replacement indicated that SNAC heparin in two different doses was as effective and safe as UFH given subcutaneously. A phase III clinical trial comparing two doses of SNAC heparin given orally with LMWH by subcutaneous injection for the prevention of venous thromboembolism in patients undergoing total hip replacement is currently underway.